Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

Launched by FUNDACIÓN INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEÓN · Oct 17, 2018

Keywords

ClinConnect Summary

The CARTIER clinical trial is studying how to better protect the hearts of elderly patients with certain types of cancer, such as colon cancer, breast cancer, and lymphoma, while they receive cancer treatment. This trial compares two approaches: one that involves close heart monitoring and care by a specialized team focused on preventing heart problems (called cardiotoxicity) and another that follows the standard practice where heart monitoring is not routinely done. The main goal is to see if the first approach reduces the risk of death from all causes compared to the standard care.

To participate in this trial, patients need to be 65 years or older, have a diagnosed cancer type mentioned above, and expect to live for at least another year. They will need to sign a consent form to take part. Over the next 2 to 5 years, the study will track different health outcomes, including heart and cancer-related deaths, hospitalizations, and overall healthcare costs. This research aims to find the best way to ensure that elderly cancer patients not only survive their cancer treatment but also maintain their heart health during and after treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \> 65 years old
• • Expected survival \>1 year
• • Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma
• • Signature on the informed consent
• Exclusion Criteria:
• • Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included
• • Patients who had received previous potentially cardiotoxic anticancer treatment